7-alpha-hydroxy-DHEA

7-Alpha-Hydroxy-DHEA (7α-OH-DHEA): A Comprehensive Reference

1. Identity, Nomenclature, and Chemical Nature

7α-Hydroxydehydroepiandrosterone (7α-hydroxy-DHEA; 7α-OH-DHEA), also known as 3β,7α-dihydroxyandrost-5-ene-17-one, is an endogenous, naturally occurring steroid and a major metabolite of dehydroepiandrosterone (DHEA) that is formed by CYP7B1 (steroid 7α-hydroxylase) in tissues such as the prostate gland and by CYP3A4 in the liver.

The compound is registered in chemical databases under the following identifiers and synonyms:

• IUPAC name: (3β,7α)-3,7-Dihydroxyandrost-5-en-17-one; also recorded as 3β,7α-Dihydroxy-5-androstene-17-one and 3β,7α-dihydroxyandrost-5-en-17-one.
• CAS Registry Number: 53-00-9
• Molecular formula: C₁₉H₂₈O₃
• Common synonyms: 7a-Hydroxy-Dehydroepiandrosterone, 7-Alfa-Hidroxi-DHEA, 7-Alpha-Hydroxy-Dehydroepiandrosterone, 7-Alpha-OH-DHEA, 7-Hydroxy-Dehydroepiandrosterone, 7-Hydroxy DHEA, 7-OH-DHEA.

Structurally, 7α-OH-DHEA is a C19 androstane-series steroid possessing three oxygen-bearing positions: a 3β-hydroxyl, a 7α-hydroxyl (the defining modification from DHEA), and a 17-ketone. It belongs to the broader family of oxygenated DHEA metabolites, which also includes the stereoisomeric 7β-hydroxy-DHEA and the oxidized derivative 7-oxo-DHEA (7-keto-DHEA); these three compounds are biochemically interconvertible but are distinct entities with different biological profiles.

2. Biosynthesis and Natural Source

7α-Hydroxy-DHEA is a 7α-hydroxylated metabolite of DHEA, catalyzed by intracellular steroid 7α-hydroxylases such as P450 2A1 (and in humans predominantly CYP7B1). Both 7α-hydroxy-DHEA and 7β-hydroxy-DHEA are naturally circulating in humans as DHEA metabolites originating from the liver, brain, and skin. In humans, mice, and rats, the 7α-hydroxylation of DHEA is carried out by the specific cytochrome P450 7B1 (CYP7B1) expressed in these tissues.

The major metabolic pathway of DHEA outside the liver is via 7-hydroxylation into 7α-OH-DHEA and 7β-OH-DHEA. Within the brain specifically, the neurosteroids pregnenolone and dehydroepiandrosterone are precursors for both oxidized and hydroxylated metabolites; brain production of 7-hydroxylated derivatives is second to that in the liver, and the P4507B1-containing hippocampus is the major site for 7α-hydroxylation.

The cytochrome P4507B1 in the human hippocampus is responsible for the production of 7α-hydroxylated derivatives of DHEA and other 3β-hydroxylated neurosteroids; minor quantities of the 7β-hydroxylated derivatives are also produced.

Once formed, 7α-OH-DHEA enters a reversible metabolic triangle: the synthesis of 7-keto-DHEA begins with an irreversible hydroxylation of DHEA in the position C7 by CYP7B1 to form 7α-OH-DHEA, which 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) then uses as a substrate, catalyzing the interconversion of 7α-OH-DHEA and 7β-hydroxy-DHEA through a 7-keto-DHEA intermediary.

The prostate gland is a notable peripheral site of production: the V(max) value of the prostate for this reaction was 46±2 pmol/min per mg, and this activity was inhibited by clotrimazole, a P450-enzyme blocker; RNA analysis revealed a high expression of CYP7B1 mRNA in the rat prostate, restricted to the epithelium, suggesting that CYP7B1 catalyses 7α-hydroxylation in the prostate gland.

7α- and 7β-hydroxylated metabolites of DHEA are present in near-nanomolar concentrations in human blood. Because the compound is a product of enzymatic metabolism, there are no food sources of DHEA itself; wild yams contain a substance similar to DHEA used to make DHEA in the laboratory, while the body manufactures DHEA naturally in the adrenal glands. 7α-OH-DHEA is therefore obtained endogenously from DHEA rather than from any dietary botanical source.

3. Traditional and Historical Use

7α-OH-DHEA has no documented history of traditional, folkloric, or ethnomedicinal use in its own right. It was unknown as a discrete entity to pre-scientific medical traditions because it is an endogenous metabolite identified only through modern analytical biochemistry. Its precursor DHEA was itself not isolated until the early twentieth century, and 7α-OH-DHEA was characterized decades later through gas chromatography–mass spectrometry techniques.

Research interest in the compound emerged in the latter decades of the twentieth century, principally from laboratory investigations of DHEA metabolism. Nearly 60 years has elapsed since the first isolation and identification of 7α-hydroxy-dehydroepiandrosterone, and in that time much information has been gained on its occurrence, metabolism, ontogeny, immunomodulatory activity, cell proliferation, cortisol control in local tissues, and neuroactivity. Commercial interest in 7α-OH-DHEA as a stand-alone dietary supplement arose in the context of broader market interest in DHEA and its oxygenated congeners during the 1990s and 2000s, particularly following early patent filings covering its potential use in weight management and immune modulation.

4. Key Active Compounds, Biochemical Context, and Mechanisms of Action

4.1 Relationship to DHEA and the 7-Oxysteroid Family

7α-OH-DHEA is not pharmacologically independent of the DHEA metabolic network. 7α-Hydroxy-DHEA exhibits biological activity comparable to DHEA but does not convert into compounds with androgenic or estrogenic activity — a critical distinction from DHEA itself, which can be a precursor to sex hormones. It should not be confused with 7β-hydroxy-DHEA or 7-keto-DHEA, which are related but structurally and functionally distinct compounds.

4.2 Weak Estrogenic Activity via ERβ

7α-OH-DHEA has weak estrogenic activity, selectively activating the estrogen receptor ERβ. Although 7α-OH-DHEA is a less efficient ERβ activator than 3βAdiol, it is a candidate natural ligand for ERβ. In humans, the concentration of 7α-OH-DHEA in serum is strongly correlated with that in cerebrospinal fluid.

4.3 Antiglucocorticoid Mechanisms

7α-OH-DHEA may be responsible for the known antiglucocorticoid effects of DHEA. The proposed mechanism involves competition with glucocorticoids at the level of 11β-HSD1: 7α-hydroxy-DHEA produced by CYP7B1 is a substrate for 11β-HSD1, which exists in the same tissues and carries out the interconversion of 7α- and 7β-hydroxy-DHEA through a 7-oxo intermediary. Since the role of 11β-HSD1 is to transform the inactive cortisone into active cortisol, its competitive inhibition by 7α-hydroxy-DHEA may support the paradigm of native anti-glucocorticoid arising from DHEA.

CYP7B1 7α-hydroxylates pregnenolone and DHEA into their more active 7α-hydroxylated metabolites, which are also substrates for 11β-HSD1; if levels of these 7α-hydroxylated metabolites within specific cells become high enough, they may compete with the inactive glucocorticoids for 11β-HSD1 and effectively act as endogenous "inhibitors" of 11β-HSD1 amplification of intracellular glucocorticoid action.

However, a study using transfected COS-7 cells found that treatment with 10⁻¹² to 10⁻⁵ M DHEA, 7α-hydroxy-DHEA, and 7β-hydroxy-DHEA caused no change in glucocorticoid-induced glucocorticoid receptor (GR) transactivation, and the addition of 10⁻⁵ M DHEA, 7α-hydroxy-DHEA, or 7β-hydroxy-DHEA did not change the kinesis and intensity of GR nuclear translocation. These results contribute to knowledge of 7α-hydroxy-DHEA in relation to antiglucocorticoid activity, and the authors concluded that direct interference with GR trafficking can be discounted in the case of these hormones, therefore proposing new possibilities of investigation. Accordingly, the mechanism of antiglucocorticoid action appears to operate primarily through 11β-HSD1 enzyme competition rather than through direct receptor antagonism.

4.4 Thermogenic Enzyme Induction

7α-Hydroxy-DHEA induces the activity of thermogenic enzymes such as mitochondrial sn-glycerol-3-phosphate dehydrogenase and cytosolic malic enzyme, enhancing heat production and reducing food utilization efficiency. This mechanism was identified in animal (rodent) studies and has been proposed as the basis for metabolic effects attributed to oxygenated DHEA metabolites broadly. When fed to rats, each of the 7-oxygenated DHEA derivatives induced the formation of two thermogenic enzymes in the liver.

4.5 Neuroprotective Properties

Both 7α- and 7β-hydroxy-DHEA were efficient in preventing the nuclear uptake of [³H]dexamethasone-activated glucocorticoid receptor in brain cells. Activation of 7α-hydroxylation by increased close contacts of astrocytes and after glucocorticoid treatment suggested that the regulated production of 7α-hydroxysteroids was a key event for the neuroprotection conferred by neurosteroids.

DHEA and epiandrosterone were ineffective in protecting organotypic hippocampal slice cultures against hypoxia/reperfusion-induced neuronal cell death, whereas their corresponding 7-hydroxy derivatives had powerful neuroprotective effects. Therefore, 7-hydroxy DHEA and 7-hydroxy EPIA may be endogenous neuroprotective agents, and 7-hydroxylation of DHEA and EPIA may be impaired in neurodegenerative conditions such as Alzheimer's disease.

4.6 Immunomodulatory Action

In human and murine lymphoid organs, circulating 3β-hydroxysteroids including DHEA are 7α-hydroxylated by a cytochrome P450 identified in the hippocampus as P4507B1. Both 7α-hydroxy-DHEA and 7α-hydroxy-epiandrosterone triggered a significant increase of antitetanus toxoid and anti-Bordetella pertussis toxin IgG production in cultures of activated B + T cells derived from human tonsils.

5. Scientific Evidence by Area of Research

5.1 Aging and Age-Related Decline

7α-Hydroxy-DHEA levels in the body decrease with age, generating interest in using supplements to slow aging. This age-related decline has been documented in clinical observational studies. A study measuring both 7-hydroxy-DHEA epimers in sera from 252 males and 172 females found that in men, a distinct decline with age occurred, while in females, two local maxima were recorded around age 22 and 53, respectively.

A further study of 213 healthy Central European males aged 50 to 91 years confirmed that in men, a distinct decline in 7α-hydroxy-dehydroepiandrosterone with age was observed, and the curves for age dependence of 7-hydroxy metabolite levels in males resembled those previously determined for unconjugated dehydroepiandrosterone.

The enzyme responsible for its synthesis also declines with age: like the levels of circulating DHEA, the activity of these hydroxylating enzymes decreases with age. Furthermore, DHEA and the production of its 7-hydroxylated derivatives decrease with age although that of the glucocorticoids does not vary; in the course of aging, the hormonal steroid contribution at the cutaneous level is therefore found to be modified with a predominance of glucocorticoids, whose promoter effects on cutaneous aging are known.

Evidence strength: The age-related decline in 7α-OH-DHEA is well-established by observational cross-sectional studies in humans. No controlled intervention trials directly testing 7α-OH-DHEA supplementation in aging humans have been identified in authoritative databases. Evidence that supplementing 7α-OH-DHEA reverses or modifies aging processes in humans is absent.

5.2 Immune System Modulation

7-Hydroxylated metabolites of DHEA are believed to be responsible for at least some immunomodulatory and antiglucocorticoid effects of DHEA and hence are considered candidates for hormone replacement therapy.

In vitro research using human tonsil-derived cell cultures demonstrated that both 7α-hydroxy-DHEA and 7α-hydroxy-epiandrosterone triggered a significant increase of antitetanus toxoid and anti-Bordetella pertussis toxin IgG production in cultures of activated B + T cells derived from human tonsils; this paracrine action of 7α-hydroxysteroids resulted from their production in cells of the lymphoid organs.

In a study using murine splenocyte cultures, the effect of dexamethasone and three potential antiglucocorticoids — DHEA and its 7α- and 7β-hydroxylated metabolites — on primary immune response was studied by measuring the number of plaque-forming cells (PFC). Dexamethasone suppressed considerably the PFC as well as their viability, but DHEA as well as its 7α-hydroxylated metabolite also decreased significantly the PFC, while the effect of 7β-hydroxy-DHEA was different. This finding complicated interpretations of 7α-OH-DHEA as a simple antiglucocorticoid immunostimulant.

Experiments in vitro brought evidence that 7β-OH-DHEA, but not DHEA and its 7α-hydroxy isomer, could counteract the immunosuppressive effect of dexamethasone on the formation of plaques in culture of murine spleen lymphocytes.

Evidence strength: Evidence is predominantly preclinical (in vitro and animal). The immunostimulant signal for 7α-OH-DHEA in human tonsil cell cultures is intriguing but limited in scope. No human clinical trial directly assessing immune outcomes following 7α-OH-DHEA supplementation has been identified in the peer-reviewed literature. The distinction between 7α- and 7β-epimers in immune effects is not fully resolved.

5.3 Neuroscience: Cognition, Neuroprotection, and Alzheimer's Disease

Neuroactive steroids termed neurosteroids are synthesized locally in the brain and influence biological functions including cognition and behavior. Among them, CYP7B1 catalyzes the formation of 7α-OH-DHEA in the hippocampus. Research demonstrated the occurrence of this neurosteroid in the mouse hippocampus after spatial-learning tasks, and CYP7B1 deficiency impaired remote spatial memory with recent memory mostly unaffected.

The hippocampal dendritic spine densities were reduced in CYP7B1-deficient mice, and they were no longer increased by training. Furthermore, chronic intracerebroventricular administration of a mixture of 7α-OH-pregnenolone and 7α-OH-DHEA rescued the deteriorated remote memory performance in CYP7B1-deficient mice. This is rodent data only.

The relationship between 7α-OH-DHEA and Alzheimer's disease (AD) is complex and somewhat paradoxical. Serum levels of 7α-OH-DHEA have been found to be significantly elevated in patients with Alzheimer's disease; it is unclear what significance this may have, if any.

The original 1998 study measuring serum 7α-OH-DHEA in AD was small: using gas chromatography/mass spectrometry on trifluoroacetate derivatives, levels of free 7α-hydroxy-DHEA and its sulfated conjugate and fatty acid esters were measured in serum of 10 female patients with AD and 8 age-matched healthy control women. Free 7α-hydroxy-DHEA levels in AD and controls were not significantly different, but sulfate conjugate levels were significantly increased in AD (p = .01), and total 7α-hydroxy-DHEA produced was significantly increased in AD (p = .024).

On the enzyme side, research found that CYP7B mRNA was significantly decreased (approximately 50% decline; P<0.05) in dentate neurons from AD subjects compared with controls. A decline in CYP7B activity may contribute to the loss of effects of DHEA with ageing and perhaps to the pathophysiology of AD.

High levels of CYP7B1 are expressed in the hippocampus, and enzyme activity is selectively decreased in aged rats with impaired spatial memory but not in aged cognitively unimpaired rats.

Changes in the ratio of 7α/7β-hydroxy-DHEA were seen in patients with dementia, and this ratio was sufficient for the differentiation between vascular and Alzheimer's dementia.

Additional knowledge about this steroid may elucidate its role in obesity, neurodegenerative disturbances such as Alzheimer's disease, or psychiatric disorders such as schizophrenia or depression.

Evidence strength: All neurological data are preclinical (animal models, in vitro, or small observational studies). The direction of the relationship with Alzheimer's disease (elevated total 7α-OH-DHEA yet reduced CYP7B1 activity) is not fully reconciled in the literature. No human clinical trial exists.

5.4 Body Weight and Metabolism

7α-Hydroxy-DHEA induces the activity of thermogenic enzymes such as mitochondrial sn-glycerol-3-phosphate dehydrogenase and cytosolic malic enzyme, enhancing heat production and reducing food utilization efficiency. As a more efficient and safer metabolite compared to DHEA, 7α-Hydroxy-DHEA holds potential for studies in the fields of obesity and metabolic diseases. This characterization, however, derives primarily from animal studies.

Much of the clinical research on thermogenesis in the DHEA oxysterol family was conducted on 7-oxo-DHEA (7-keto-DHEA), not 7α-OH-DHEA directly. The synthesis of 7-keto-DHEA begins with an irreversible hydroxylation of DHEA by CYP7B1 forming 7α-OH-DHEA, which 11β-HSD1 then converts through a 7-keto-DHEA intermediary. The thermogenic signal attributed to 7α-OH-DHEA in rodent liver enzyme induction studies has not been replicated in controlled human trials specific to 7α-OH-DHEA.

People take 7-alpha-hydroxy-DHEA for aging, obesity, muscle strength, and many other purposes, but there is no good scientific evidence to support these uses.

Evidence strength: Preclinical only. No controlled human clinical trials of 7α-OH-DHEA for obesity or body composition have been identified.

5.5 Skin and Dermatological Applications

Patent-level research has explored 7α-OH-DHEA in cosmetic and dermatological formulations. Among the metabolites of DHEA, particular attention has been paid to 7α-hydroxy-DHEA. It has been demonstrated that this metabolite, which does not possess the hormonal activity of DHEA, increased the proliferation of fibroblasts and the viability of human keratinocytes and had anti-free radical effects; it was also demonstrated, in rats, that 7α-hydroxy-DHEA increased the thickness of the dermis and the elastin and collagen content of the skin.

It has been suggested to use this metabolite of DHEA for preventing and/or treating the harmful effects of UV radiation on the skin, for controlling wrinkles, and for increasing skin firmness and tone.

Research has allowed demonstration that the effects of glucocorticoids leading to cell apoptosis are cancelled out by the 7-hydroxylated steroids and that their action on the cutaneous cells is manifested by beneficial and protective effects.

Evidence strength: Preclinical and patent-disclosure level only. Controlled clinical trials in humans for skin aging or dermatological conditions have not been identified.

5.6 Antioxidant Activity

7α-Hydroxy-DHEA might also stimulate the immune system and might act like an antioxidant. The antioxidant characterization derives from animal tissue studies (referenced in the literature as Pelissier et al., examining antioxidant effects of DHEA and 7α-hydroxy-DHEA in rat colon, intestine, and liver). No human intervention studies on antioxidant outcomes are available for 7α-OH-DHEA specifically.

Evidence strength: Animal/in vitro data only. Human evidence is absent.

6. Body Systems Associated with 7α-OH-DHEA

• Endocrine/Adrenal system: Formed as a metabolite from adrenal DHEA; participates in the local glucocorticoid regulatory axis via 11β-HSD1.
• Central nervous system / Hippocampus: The neurosteroids pregnenolone and DHEA are precursors for hydroxylated metabolites in the brain; the P4507B1-containing hippocampus is the major brain site for 7α-hydroxylation.
• Immune system: Evidence has been accumulating that 7-hydroxyepimers of dehydroepiandrosterone may act as locally active immunomodulatory and immunoprotective agents, counteracting the actions of glucocorticoids.
• Skin: CYP7B1 and 11β-HSD1 are both expressed in skin, making the skin an active site of 7α-OH-DHEA production and action.
• Prostate: High expression of CYP7B1 mRNA in the rat prostate, restricted to the epithelium, suggests that CYP7B1 catalyses 7α-hydroxylation in the prostate gland.
• Liver: A primary site of 7α-hydroxylation of DHEA and of thermogenic enzyme induction in animal studies.

7. Dosage Forms and Reported Dosages

7α-OH-DHEA is available commercially as an oral dietary supplement, typically in capsule form. It may also appear in topical cosmetic and skin-care preparations, as suggested by patent filings describing dermatological compositions containing 7-hydroxy-DHEA and/or 7-keto-DHEA.

Regarding oral dosing in humans: when taken by mouth, there is not enough reliable information to know if 7α-hydroxy-DHEA is safe or what the side effects might be. There is not enough reliable information to know what an appropriate dose of 7α-hydroxy-DHEA might be. No peer-reviewed human clinical trials specifying studied dose ranges for this specific compound have been identified in authoritative databases.

Plasma levels in healthy subjects have been measured in the nanomolar range: 7α- and 7β-hydroxylated metabolites of DHEA are present in near-nanomolar concentrations in human blood. The 1998 Alzheimer's disease study reported baseline free 7α-OH-DHEA levels of approximately 206–240 pg/mL in serum of control and AD women measured by GC/MS.

8. Safety Considerations and Drug Interactions

8.1 General Safety Profile

When taken by mouth, there is not enough reliable information to know if 7α-hydroxy-DHEA is safe or what the side effects might be. The absence of human clinical trial data means that a formal safety profile has not been established.

8.2 Non-Androgenic and Non-Estrogenic Differentiation from DHEA

A potentially favorable safety attribute relative to DHEA itself is that 7α-Hydroxy-DHEA exhibits biological activity comparable to DHEA but does not convert into compounds with androgenic or estrogenic activity. This distinguishes it from DHEA, which can serve as a precursor to androgens and estrogens, producing corresponding hormonal side effects. This claim, however, derives from in vitro and animal metabolic pathway studies rather than human pharmacokinetic data.

8.3 WADA Prohibition in Sport

7α-OH-DHEA is on the World Anti-Doping Agency (WADA) list of prohibited substances in sporting. This prohibition applies to competitive athletes subject to anti-doping regulations. The prohibition reflects regulatory concern about potential performance-enhancement or masking effects, consistent with its classification as a steroid metabolite, rather than a finding of confirmed ergogenic effect in human studies.

8.4 Distinction from Related Compounds

7α-Hydroxy-DHEA should not be confused with 7β-hydroxy-DHEA, 7-keto-DHEA, or DHEA. These are not the same. The three oxygenated DHEA metabolites have different biological profiles, and evidence from one cannot be freely extrapolated to the others.

8.5 Known Drug and Supplement Interactions

It is not known whether 7α-hydroxy-DHEA interacts with any medicines. There are no known interactions with herbs and supplements, and there are no known interactions with foods. This reflects the current state of ignorance rather than established safety; the absence of interaction data is a consequence of the absence of clinical trials.

8.6 11β-HSD1 Interference: Potential Glucocorticoid-Related Considerations

A mechanistically relevant safety consideration is the compound's documented competitive interaction with 11β-HSD1: inhibition of cortisol oxidation by 7α-hydroxy-DHEA was competitive with a Kᵢ at 1.85 ± 0.495 μM; these findings may support the previously proposed native anti-glucocorticoid paradigm and suggest that 7α-hydroxy-DHEA production is a key for the fine tuning of glucocorticoid levels in tissues. In principle, significant supplementation with 7α-OH-DHEA could alter local glucocorticoid activation in tissues expressing 11β-HSD1 (liver, brain, skin, adipose tissue); however, the clinical significance of this in humans at supplemental doses has not been studied.

9. Summary of Evidence Characterization

Across all areas of potential use, the scientific evidence for 7α-OH-DHEA as a human dietary supplement remains at a preclinical stage. People take 7-alpha-hydroxy-DHEA for aging, obesity, muscle strength, and many other purposes, but there is no good scientific evidence to support these uses. The compound has a well-characterized endogenous biochemistry and a number of biologically plausible mechanisms identified in cell culture and animal models; however, none of these have been translated into controlled human clinical trials that demonstrate benefit for any health outcome. The compound's role as an endogenous steroid metabolite, its apparent non-conversion to androgens or estrogens, and its immunomodulatory and neuroprotective signals in preclinical models make it an area of ongoing scientific interest. Additional knowledge about this steroid may elucidate its role in obesity, neurodegenerative disturbances such as Alzheimer's disease, or psychiatric disorders such as schizophrenia or depression.

References

• PubChem: 7alpha-Hydroxy-DHEA (CID 65517) — National Center for Biotechnology Information
• ChemSpider: 7α-Hydroxy-DHEA — Royal Society of Chemistry
• Wikipedia: 7α-Hydroxy-DHEA
• Morfin R, Lafaye P, Cotillon AC, et al. 7 alpha-hydroxy-dehydroepiandrosterone and immune response. Ann N Y Acad Sci 2000;917:971–82 — PubMed
• Hampl R, Morfin R, Starka L. 7-Hydroxydehydroepiandrosterone — a natural antiglucocorticoid and a candidate for steroid replacement therapy? Endocr Regul 2000 — PubMed
• Dehydroepiandrosterone and its 7-hydroxylated metabolites do not interfere with the transactivation and cellular trafficking of the glucocorticoid receptor — PubMed
• Yau JL et al. Dehydroepiandrosterone 7-hydroxylase CYP7B: predominant expression in primate hippocampus and reduced expression in Alzheimer's disease. Neuroscience 2003 — PubMed
• Attal-Khemis S et al. Increased total 7 alpha-hydroxy-dehydroepiandrosterone in serum of patients with Alzheimer's disease. J Gerontol A Biol Sci Med Sci 1998 — PubMed
• Starka L, Hampl R, Hanus M, et al. Plasma levels of 7-hydroxymetabolites of dehydroepiandrosterone in healthy Central European aging men. Clin Chem Lab Med 2005 — PubMed
• 7-Hydroxydehydroepiandrosterone epimers in the life span — PubMed
• cyp7b1 catalyses the 7alpha-hydroxylation of dehydroepiandrosterone and 25-hydroxycholesterol in rat prostate — PubMed
• Morfin R, Starka L. Neurosteroid 7-hydroxylation products in the brain — PubMed
• Hippocampal 7α-Hydroxylated Neurosteroids Are Raised by Training and Bolster Remote Spatial Memory with Increase of the Spine Densities — PubMed
• Biosynthesis of [3H]7 alpha-hydroxy-, 7 beta-hydroxy-, and 7-oxo-dehydroepiandrosterone using pig liver microsomal fractions — PubMed
• Inter-conversion of 7α- and 7β-hydroxy-dehydroepiandrosterone by the human 11β-hydroxysteroid dehydrogenase type 1 — ScienceDirect / Journal of Steroid Biochemistry and Molecular Biology
• Local amplification of glucocorticoids in the aging brain and impaired spatial memory — Frontiers in Aging Neuroscience
• A systematic review of the impact of 7-keto-DHEA on body weight — PMC / Archives of Gynecology and Obstetrics
• Sex differences in the serum level of endogenous ligands for estrogen receptor β in the elderly population — PMC
• WebMD / Natural Medicines: 7-alpha-hydroxy-DHEA Monograph
• LearnSkin / Natural Medicines Database: 7-alpha-hydroxy-DHEA
• US Patent 5,506,223: Δ5-Androstenes useful for promoting weight maintenance or weight loss — USPTO
• US Patent 6,620,803: Cosmetic or dermatological use of 7-hydroxylated steroids — USPTO
• US Patent 6,994,864: Composition containing 7-hydroxy DHEA and/or 7-keto DHEA and at least a carotenoid — USPTO